/Cdx-2 AA Variant of Defines the Response to Phototherapy Amongst Patients with Psoriasis

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Jul 2

PMID 34208603

Citations 4

Authors

Aleksandra Lesiak

Karolina Wodz

Magdalena Ciazynska

Malgorzata Skibinska

Michal Waszczykowski

Karol Ciazynski

Irmina Olejniczak-Staruch

Dorota Sobolewska-Sztychny

Joanna Narbutt

Affiliations

Soon will be listed here.

Abstract

1,25-dihydroxyvitamin-D plays a central role in the immune system via binding to the vitamin D receptor. polymorphisms have been associated with multiple autoimmune disorders, including psoriasis. Until now, five polymorphisms, , , , and /Cdx2, have been studied in psoriasis, with contradicting results. Therefore, this study aimed to evaluate the association of polymorphisms with susceptibility to psoriasis, effectiveness of NB-UVB phototherapy and concentration of proinflammatory cytokines and vitamin D amongst the Polish population. polymorphisms were analyzed by PCR-RFLP or real-time PCR. We found that the frequency of the /Cdx-2 GG genotype was significantly higher in psoriasis patients and was associated with regulation of IL-17 and IL-23 concentration. Moreover, /Cdx-2 AA might have a significant effect on the response to phototherapy amongst patients with psoriasis. Our results suggest that VDR is a susceptibility factor for psoriasis development. Moreover, /Cdx-2 variants have a significant effect on the response to phototherapy amongst patients with psoriasis and regulation of inflammatory response via decrease of IL-17 and IL-23 level after UVB phototherapy in the Polish population. Results of our study provide some evidence in support of the hypothesis that the vitamin D signaling pathway may be of relevance for pathogenesis and treatment of psoriasis.

Citing Articles

The rs11568820 Variant in the Promoter Region of Vitamin D Receptor Gene Is Associated with Clinical Remission in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.

Latini A, De Benedittis G, Conigliaro P, Bonini C, Morgante C, Iacovantuono M Genes (Basel). 2024; 15(2).

PMID: 38397223 PMC: 10887840. DOI: 10.3390/genes15020234.

Modulatory role of vitamins A, B3, C, D, and E on skin health, immunity, microbiome, and diseases.

Joshi M, Hiremath P, John J, Ranadive N, Nandakumar K, Mudgal J Pharmacol Rep. 2023; 75(5):1096-1114.

PMID: 37673852 PMC: 10539462. DOI: 10.1007/s43440-023-00520-1.

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.

Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A Int J Mol Sci. 2023; 24(12).

PMID: 37372997 PMC: 10298473. DOI: 10.3390/ijms24129850.

Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy.

Brozyna A, Slominski R, Nedoszytko B, Zmijewski M, Slominski A Int J Mol Sci. 2022; 23(15).

PMID: 35955731 PMC: 9369120. DOI: 10.3390/ijms23158575.

References

Chan J, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S . IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203(12):2577-87. PMC: 2118145. DOI: 10.1084/jem.20060244. View

Matos T, Sheth V . The symbiosis of phototherapy and photoimmunology. Clin Dermatol. 2016; 34(5):538-47. DOI: 10.1016/j.clindermatol.2016.05.003. View

Reich A, Orda A, Wisnicka B, Szepietowski J . Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol. 2007; 87(4):299-304. DOI: 10.2340/00015555-0265. View

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View

Deeb K, Trump D, Johnson C . Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7(9):684-700. DOI: 10.1038/nrc2196. View

Matos T, Ling T, Sheth V . Ultraviolet B radiation therapy for psoriasis: Pursuing the optimal regime. Clin Dermatol. 2016; 34(5):587-93. DOI: 10.1016/j.clindermatol.2016.05.008. View

Iwakura Y, Ishigame H, Saijo S, Nakae S . Functional specialization of interleukin-17 family members. Immunity. 2011; 34(2):149-62. DOI: 10.1016/j.immuni.2011.02.012. View

Gallo E, Cabaleiro T, Roman M, Solano-Lopez G, Abad-Santos F, Garcia-Diez A . The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study. Br J Dermatol. 2013; 169(4):819-29. DOI: 10.1111/bjd.12425. View

Danielsen K, Duvetorp A, Iversen L, Ostergaard M, Seifert O, Tveit K . Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Derm Venereol. 2018; 99(1):18-25. DOI: 10.2340/00015555-3017. View

10.

Zhou X, Xu L, Li Y . The association of polymorphisms of the vitamin D receptor gene with psoriasis in the Han population of northeastern China. J Dermatol Sci. 2013; 73(1):63-6. DOI: 10.1016/j.jdermsci.2013.08.014. View

11.

Ling T, Clayton T, Crawley J, Exton L, Goulden V, Ibbotson S . British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. Br J Dermatol. 2016; 174(1):24-55. DOI: 10.1111/bjd.14317. View

12.

German B, Wei R, Hener P, Martins C, Ye T, Gottwick C . Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight. 2019; 4(2). PMC: 6413797. DOI: 10.1172/jci.insight.123390. View

13.

Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2009; 62(1):114-135. DOI: 10.1016/j.jaad.2009.08.026. View

14.

Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

15.

Di Cesare A, Di Meglio P, Nestle F . The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129(6):1339-50. DOI: 10.1038/jid.2009.59. View

16.

Talamonti M, Galluzzo M, van den Reek J, de Jong E, Lambert J, Malagoli P . Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017; 177(2):489-496. DOI: 10.1111/bjd.15387. View

17.

Li K, Huang C, Randazzo B, Li S, Szapary P, Curran M . HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. J Invest Dermatol. 2016; 136(12):2364-2371. DOI: 10.1016/j.jid.2016.06.631. View

18.

. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2012; 9(27):1-66. PMC: 3377497. View

19.

Boehncke W, Schon M . Psoriasis. Lancet. 2015; 386(9997):983-94. DOI: 10.1016/S0140-6736(14)61909-7. View

20.

Park B, Park J, Lee D, Youn J, Kim I . Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol. 1999; 112(1):113-6. DOI: 10.1046/j.1523-1747.1999.00482.x. View